Abstract 2694
Background
In advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly improved patients (pts) prognosis, even if many factors could impair their efficacy. The impact of steroids (well below the immunosuppressant dose) on ICIs outcomes is debatable, although a quite number of pts starts immunotherapy while on, or early recurs to steroids as supportive care medications or for mild AEs. Here, we aimed at assessing the impact of early steroids use on clinical outcomes of ICIs treatment in a series of pts with advanced NSCLC.
Methods
All consecutive pts with advanced NSCLC who started ICIs at our institution from Apr 2013 to Dec 2017 were retrospectively reviewed. Pts with at least one instrumental response assessment were included. Early use of steroids was defined as the use of a daily prednisone-equivalent dose ≥ 10 mg for at least 1 day within 28 days from ICIs initiation. Chi-square test or Fisher's exact test were used to analyze the association of early use of steroids with pts’ characteristics. The Kaplan-Meier method and the Cox proportional-hazards model were used for survival analyses.
Results
Out of 151 pts included, 35 (23 %) made early use of steroids. Most of the pts (96%) received single agent anti PD-1/PD-L1, while 6 pts (4%) received combinatorial PD-L1+CTLA-4 blockade. Early use of steroids was negatively associated with disease control (OR 0,32; 95% CI 0.14-0.71, P = .006) and positively associated with ≥2 metastatic sites (OR 3,08, 95% CI 1.33-7.89; P = .01) and ECOG PS ³ 2 (OR 4.57; 95% CI 1.10-20.37; P = .03). With a median follow-up of 32.7 months, early use of steroids conferred a worse median progression-free survival (PFS) (1.98 vs 3.94 months; HR 1.80; 95% CI 1.20-2.80; P = .003). In the multivariable model including other covariates significantly associated with PFS (i.e. ECOG PS and PD-L1 status), the early use of steroids was confirmed to be independently associated with poorer PFS (HR 1.88; 95% CI 1.08-3.28; P = .03).
Conclusions
We found that the early use of steroids independently affects clinical outcomes in patients with advanced NSCLC treated with ICIs. If these findings will be further validated, such use in this setting should be carefully evaluated and avoided when not strictly needed.
Clinical trial identification
Legal entity responsible for the study
Giovanni Fucà.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
D. Signorelli: Consultancies: AstraZeneca, Boehringer Ingelheim, BMS. M.C. Garassino: Consultancies: MSD, BMS, AstraZeneca, Eli Lilly. C. Proto: Consultancies: MSD, BMS. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract